Reasons to go for Rezūm steam therapy: an effective and durable outpatient minimally invasive procedure.
BPH
Rezūm LUTS
Surgery
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
21
04
2020
accepted:
10
09
2020
pubmed:
25
9
2020
medline:
30
11
2021
entrez:
24
9
2020
Statut:
ppublish
Résumé
In this review, we will discuss the state of the literature regarding Rezūm and opportunities for its application in the treatment of BPH. A comprehensive review of original research on convective water vapor thermal therapy (Rezūm) was conducted. Articles related to transurethral resection of the prostate, holmium laser enucleation of the prostate, Aquablation, and greenlight photoselective vaporization of the prostate were reviewed for discussion. Rezūm distinguishes itself from other treatment options by its durable improvement in objective clinical outcomes such as IPSS and BPH Impact Index, while being cost-effective and versatile in its ability to treat a variety of prostate gland morphologies. This treatment option shows good lower urinary tract symptom relief, especially in small-to-moderate prostate sizes (30-80 cc). The use of convective heat transfer is unique and allows for localized treatment, avoiding damage to surrounding structures, thus providing an excellent safety profile and sexual function preservation. The current evidence on Rezūm warrants its consideration as a therapeutic alternative to transurethral surgery in selected patients.
Identifiants
pubmed: 32968851
doi: 10.1007/s00345-020-03457-9
pii: 10.1007/s00345-020-03457-9
doi:
Substances chimiques
Steam
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2307-2313Informations de copyright
© 2020. Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Chughtai B, Forde JC, Thomas DDM et al (2016) Benign prostatic hyperplasia. Nat Rev Dis Prim 2:1–15. https://doi.org/10.1038/nrdp.2016.31
doi: 10.1038/nrdp.2016.31
Benign Prostatic Hyperplasia (BPH) Guideline—American Urological Association. https://www.auanet.org/guidelines/benign-prostatic-hyperplasia-(bph)-guideline#x8218 . Accessed 2 Apr 2020
Gravas S, Cornu JN, Gacci M et al (2020) EAU Guidelines: Management of Non-neurogenic Male LUTS, incl. Benign prostatic obstruction (BPO). https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/ . Accessed 17 Apr 2020
Van Asseldonk B, Barkin J, Elterman DS (2015) Medical therapy for benign prostatic hyperplasia: a review. Can J Urol 22(Suppl 1):7–17
pubmed: 26497339
Ahyai SA, Gilling P, Kaplan SA et al (2010) Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol 58:384–397
doi: 10.1016/j.eururo.2010.06.005
pubmed: 20825758
Foster HE, Barry MJ, Dahm P et al (2018) Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. J Urol 200:612–619. https://doi.org/10.1016/j.juro.2018.05.048
doi: 10.1016/j.juro.2018.05.048
pubmed: 29775639
Jones P, Rajkumar GN, Rai BP et al (2016) Medium-term outcomes of urolift (minimum 12 months follow-up): evidence from a systematic review. Urology 97:20–24
doi: 10.1016/j.urology.2016.05.003
Jones P, Rai BP, Nair R, Somani BK (2015) Current status of prostate artery embolization for lower urinary tract symptoms: review of world literature. Urology 86:676–681
doi: 10.1016/j.urology.2015.05.011
NX TheraInc. (2018) Instructions for Use Rezūm
McVary KT, Rogers T, Roehrborn CG (2019) Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology 126:171–179. https://doi.org/10.1016/j.urology.2018.12.041
doi: 10.1016/j.urology.2018.12.041
pubmed: 30677455
Woo HH, Gonzalez RR (2017) Perspective on the Rezūm® system: a minimally invasive treatment strategy for benign prostatic hyperplasia using convective radiofrequency water vapor thermal therapy. Med Devices Evid Res 10:71–80. https://doi.org/10.2147/mder.s135378
doi: 10.2147/mder.s135378
Cantrill CH, Zorn KC, Elterman DS, Gonzalez RR (2019) The Rezūm system—a minimally invasive water vapor thermal therapy for obstructive benign prostatic hyperplasia. Can J Urol 26:9787–9793
pubmed: 31180311
Newcastle External Assessment Centre (2019) External assessment centre report: MT413 Rezum Date. https://www.nice.org.uk/guidance/GID-MT529/documents/supporting-documentation . Accessed 3 Apr 2020
Johnston M, Shah T, Emara A et al (2019) MP01-03 Rezūm water vapour ablation therapy for benign prostatic hyperplasia: initial results from the United Kingdom. J Urol. https://doi.org/10.1097/01.JU.0000554867.66478.23
doi: 10.1097/01.JU.0000554867.66478.23
Dixon CM, Cedano ER, Pacik D et al (2016) Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. Res Reports Urol 8:207–216. https://doi.org/10.2147/RRU.S119596
doi: 10.2147/RRU.S119596
Darson MF, Alexander EE, Schiffman ZJ et al (2017) Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezūm system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Res Reports Urol 9:159–168. https://doi.org/10.2147/RRU.S143679
doi: 10.2147/RRU.S143679
Mollengarden D, Goldberg K, Wong D, Roehrborn C (2018) Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience. Prostate Cancer Prostatic Dis 21:379–385. https://doi.org/10.1038/s41391-017-0022-9
doi: 10.1038/s41391-017-0022-9
McVary KT, Gange SN, Gittelman MC et al (2016) Erectile and ejaculatory function preserved with convective water vapor energy treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: randomized controlled study. J Sex Med 13:924–933. https://doi.org/10.1016/j.jsxm.2016.03.372
doi: 10.1016/j.jsxm.2016.03.372
pubmed: 27129767
Roehrborn CG, Gange SN, Gittelman MC et al (2017) Convective thermal therapy: durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol 197:1507–1516. https://doi.org/10.1016/j.juro.2016.12.045
doi: 10.1016/j.juro.2016.12.045
pubmed: 27993667
McVary KT, Holland B, Beahrs JR (2020) Water vapor thermal therapy to alleviate catheter-dependent urinary retention secondary to benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 23:303–308. https://doi.org/10.1038/s41391-019-0187-5
doi: 10.1038/s41391-019-0187-5
pubmed: 31740738
Minimally invasive prostatic vapor ablation for the treatment of BPH in large prostates (Rezūm XL)—Full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03605745 . Accessed 9 Apr 2020
Kasivisvanathan V, Hussain M (2018) Aquablation versus transurethral resection of the prostate: 1 year United States—cohort outcomes. Can J Urol 25:9317–9322
pubmed: 29900819
Kassabian VS (2003) Sexual function in patients treated for benign prostatic hyperplasia. Lancet 361:60–62
doi: 10.1016/S0140-6736(03)12164-2
Brookes ST, Donovan JL, Peters TJ et al (2002) Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial. Br Med J 324:1059–1061. https://doi.org/10.1136/bmj.324.7345.1059
doi: 10.1136/bmj.324.7345.1059
Vale J (2000) Benign prostatic hyperplasia and erectile dysfunction– is there a link? Curr Med Res Opin 16:s63–s67. https://doi.org/10.1185/0300799009117042
doi: 10.1185/0300799009117042
Bieri S, Iselin CE, Rohner S (1997) Capsular perforation localization and adenoma size as prognostic indicators of erectile dysfunction after transurethral prostatectomy. Scand J Urol Nephrol 31:545–548. https://doi.org/10.3109/00365599709030660
doi: 10.3109/00365599709030660
Perera ND, Hill JT (1998) Erectile and ejaculatory failure after transurethral prostatectomy. Ceylon Med J 43:74–77
McVary K, Roehrborn C (2020) LBA01–06 Five year results of the prospective, randomized controlled trial of water vapor thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol. https://doi.org/10.1097/JU.0000000000000946.06
doi: 10.1097/JU.0000000000000946.06
Bouza C, López T, Magro A et al (2006) Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia. BMC Urol. 6:14
doi: 10.1186/1471-2490-6-14
pubmed: 1538609
Zlotta AR, Giannakopoulos X, Maehlum O et al (2003) Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 44:89–93. https://doi.org/10.1016/S0302-2838(03)00218-5
doi: 10.1016/S0302-2838(03)00218-5
pubmed: 12814680
Hill B, Belville W, Bruskewitz R et al (2004) Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol 171:2336–2340. https://doi.org/10.1097/01.ju.0000127761.87421.a0
doi: 10.1097/01.ju.0000127761.87421.a0
pubmed: 15126816
Rosario DJ, Phillips JT, Chapple CR (2007) Durability and cost-effectiveness of transurethral needle ablation of the prostate as an alternative to transurethral resection of the prostate when α-adrenergic antagonist therapy fails. J Urol 177:1047–1051. https://doi.org/10.1016/j.juro.2006.10.042
doi: 10.1016/j.juro.2006.10.042
pubmed: 17296409
Roehrborn CG, Barkin J, Gange SN et al (2017) Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol 24:8802–8813
pubmed: 28646935
Rassweiler J, Teber D, Kuntz R, Hofmann R (2006) Complications of transurethral resection of the prostate (TURP)-incidence, management, and prevention. Eur Urol 50:969–980
doi: 10.1016/j.eururo.2005.12.042
pubmed: 16469429
Gilling P, Barber N, Bidair M et al (2020) Three-year outcomes after aquablation therapy compared to TURP: results from a blinded randomized trial. Can J Urol 27:10072–10079. https://doi.org/10.1016/s2666-1683(20)30010-0
doi: 10.1016/s2666-1683(20)30010-0
Ulchaker JC, Martinson MS (2018) Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Clin Outcomes Res 10:29–43. https://doi.org/10.2147/CEOR.S148195
doi: 10.2147/CEOR.S148195